Brian VanderBeek, MD, MPH, MSCE
Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania
Department: Ophthalmology
Contact information
Scheie Eye Institute
51 N. 39th Street
Philadelphia, PA 19104
51 N. 39th Street
Philadelphia, PA 19104
Publications
Education:
BA (Biology)
University of Michigan, School of Literature, Science & Arts, 1999.
MPH (Toxicology)
University of Michigan, School of Public Health, 2001.
MD
University of Cincinnati College of Medicine, 2005.
MSCE
University of Pennsylvania School of Medicine, 2015.
Permanent linkBA (Biology)
University of Michigan, School of Literature, Science & Arts, 1999.
MPH (Toxicology)
University of Michigan, School of Public Health, 2001.
MD
University of Cincinnati College of Medicine, 2005.
MSCE
University of Pennsylvania School of Medicine, 2015.
Description of Clinical Expertise
Diabetic RetinopathyAge-related Macular Degeneration
Retinal Vein Occlusion
Description of Research Expertise
EpidemiologyObservational study design
Big data analysis
Selected Publications
Ying GS, VanderBeek BL.: Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Lancet Jun 2024.VanderBeek BL, Yu Y: Visual deficits due to diabetic retinal disease. Association for Research in Vision and Ophthalmology May 2024 Notes: Poster presentation.
VanderBeek BL, Yu Y, Stein JD : Visual deficits due to diabetic retinal disease. American Ophthalmology Society May 2024 Notes: poster presentation.
Tomaiuolo M, VanderBeek BL, Deaner JD, Syed ZA, Acharya B, Zhang Q, Schuman JS, Hyman L: Are Clinical Treatment Patterns for Endophthalmitis After Cataract Surgery Following the EVS Trial Recommendations? An Intelligent Research in Sight (IRIS)® Registry Analysis. Association for Research in Vision and Ophthalmology May 2024 Notes: poster presentation.
Papaliodis GN, Yu Y, Brill DA, Sobrin L, VanderBeek B.: Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis. Am J Ophthalmol 265: 241-247, Apr 2024.
Randy Dotinga: No Difference in Kidney Failure Risk Between Three Anti-VEGF Agents for Eye Disease. MedPage Today Apr 2024 Notes: https://www.medpagetoday.com/ophthalmology/generalophthalmology/109592.
VanderBeek BL.: Toward Eliminating Visual Impairment Due to Refractive Error. JAMA Ophthalmol 142: 299-300, Apr 2024.
Gupta AS, Yu Y, Orlin SE, VanderBeek BL.: Real-world socioeconomic determinants of corneal crosslinking in a national cohort. J Cataract Refract Surg 50: 217-223, Mar 2024.
VanderBeek BL, Yu Y, Oden N, VanVeldhuisen P, Blodi B, Ip M, Scott IU. : Visit Adherence and Visual Acuity in Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2). Ophthalmic Epidemiol 31(1): 78-83, Feb 2024.
Wang SY, Ravindranath R, Stein JD; SOURCE Consortium.: Prediction Models for Glaucoma in a Multicenter Electronic Health Records Consortium: The Sight Outcomes Research Collaborative. Ophthalmol Sci 4: 100445, Dec 2023.